Search results for "JUVENILE IDIOPATHIC ARTHRITIS"

showing 10 items of 37 documents

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct

Level of 25-Hydroxyvitamin D in Pediatric Arthritis Patients

2019

Abstract Vitamin D deficiency is common and widespread globally. Vitamin D has an immunomodulatory effect, but it is still unclear whether its deficiency is associated with higher disease activity. The aim of this retrospective study was to determine the serum concentration of vitamin D in children with paediatric arthritis (juvenile idiopathic arthritis and reactive arthritis). Prevalence of hypo-vitaminosis D among 98 children with juvenile idiopathic arthritis and reactive arthritis was determined and association between serum concentration of vitamin D and disease activity markers was found. Prevalence of vitamin D deficiency among children included in this study was 69.07%. Children wi…

030203 arthritis & rheumatologymedicine.medical_specialtyMultidisciplinaryScienceQArthritisvitamin d030209 endocrinology & metabolismRetrospective cohort studySerum concentrationmedicine.diseaseGastroenterologyvitamin D deficiencyreactive arthritis03 medical and health sciences0302 clinical medicinePatient ageInternal medicinejuvenile idiopathic arthritismedicineVitamin D and neurologyReactive arthritisBody mass indexProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life exp…

2022

ObjectiveInterleukin (IL)-1 inhibitors are largely employed in patients with Still’s disease; in cases with refractory arthritis, IL-6 inhibitors have shown to be effective on articular inflammatory involvement. The aim of the present study is to assess any difference in the effectiveness of the IL-1β antagonist canakinumab prescribed as first-line biologic agent between the systemic and the chronic-articular Still’s disease.MethodsData were drawn from the retrospective phase of the AutoInflammatory Disease Alliance (AIDA) international registry dedicated to Still’s disease. Patients with Still’s disease classified according to internationally accepted criteria (Yamaguchi criteria and/or Fa…

AOSD; adult onset Still’s disease; autoinflammatory diseases; biological therapy; interleukin-1; sJIA; systemic juvenile idiopathic arthritisadult onset Still’s diseaseAOSD adult onset Still’s disease autoinflammatory diseases biological therapy interleukin-1 sJIA systemic juvenile idiopathic arthritisSettore MED/38 - Pediatria Generale E Specialisticasystemic juvenile idiopathic arthritisbiological therapyAOSDGeneral Medicineautoinflammatory diseasesinterleukin-1sJIAFrontiers in Medicine
researchProduct

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease

2022

Abstract Objective To compare clinical features and treatments of patients with systemic JIA (sIJA) and adult-onset Still’s disease (AOSD). Methods The clinical charts of consecutive patients with sJIA by International League of Association of Rheumatology criteria or AOSD by Yamaguchi criteria were reviewed. Patients were seen at a large paediatric rheumatology referral centre or at 10 adult rheumatology academic centres. Data collected included clinical manifestations, inflammation biomarkers, systemic score, macrophage activation syndrome (MAS), parenchymal lung disease, disease course, disability, death and medications administered. Results A total of 166 patients (median age at diagnos…

AdultLung DiseasesBiological ProductsMacrophage Activation SyndromeArthritis JuvenileSystemic juvenile idiopathic arthritis; adult-onset Still’s diseaseRheumatologyAdrenal Cortex HormonesSystemic juvenile idiopathic arthritisAntirheumatic AgentsFerritinsPrevalenceSystemic juvenile idiopathic arthritiHumansadult-onset Still’s diseasePharmacology (medical)ChildStill's Disease Adult-OnsetBiomarkersAcute-Phase Proteins
researchProduct

Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey

2018

OBJECTIVES: To present the results of a Delphi consensus survey among Italian paediatric and adult rheumatologists on transitional care (TC) of young people (YP) with juvenile idiopathic arthritis (JIA). METHODS: A taskforce of 27 paediatric and adult rheumatologists evaluated the applicability of the 2016 EULAR/PReS recommendations for TC to the Italian rheumatology practice and healthcare system and formulated additional country-specific statements aimed to increase their suitability. After a two-round discussion, applicability of EULAR/PReS recommendations and agreement with newly-proposed statements were voted on a 0-10 scale (where 0 = no applicability/agreement and 10 = total applicab…

AdultTransition to Adult CareSettore MED/16 - REUMATOLOGIApaediatric rheumatic diseasesConsensusAdolescentJuvenileSocio-culturaleAdolescent; Adult; Child; Consensus; Humans; Italy; Surveys and Questionnaires; Arthritis Juvenile; Rheumatology; Transition to Adult Care; Transitional Carejuvenile idiopathic arthritis paediatric rheumatic diseases Delphi survey recommendations transitional care young peopleAdolescent Adult Child Consensus Humans Italy Surveys and Questionnaires Arthritis Juvenile Rheumatology Transition to Adult Care Transitional Careyoung peopleSettore MED/38 - Pediatria Generale E Specialisticayoung peopleAdolescentRheumatologySurveys and QuestionnairesHumansChildLS7_9ArthritisTransitional CareArthritis JuvenileItalyrecommendationsjuvenile idiopathic arthritisDelphi surveyjuvenile idiopathic arthritis paediatric rheumatic diseases Delphi survey recommendations transitional care young people
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

2017

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Latvian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their paren…

GerontologyMaleParentsDisease statusHealth StatusHealth-related quality of lifeArthritisDisease status; Functional ability; Health-related quality of life; JAMAR; Juvenile idiopathic arthritis; Rheumatology; Immunology and Allergy; ImmunologyDisability Evaluation0302 clinical medicineImmunology and AllergyFunctional abilityAge of OnsetChildJAMARPrognosisChild PreschoollanguageFemalemedicine.medical_specialtyDisease statusAdolescentPatientsPsychometricsImmunologyMultidimensional assessment03 medical and health sciencesRheumatologyPredictive Value of Tests030225 pediatricsInternal medicinemedicineJuvenileHumansPatient Reported Outcome MeasuresValidation Studies030203 arthritis & rheumatologyHealth related quality of lifeCultural Characteristicsbusiness.industryLatvianReproducibility of ResultsTranslatingJuvenile idiopathic arthritismedicine.diseaseLatviaFunctional abilityRheumatologylanguage.human_languageArthritis JuvenileCase-Control StudiesQuality of LifebusinessRheumatology international
researchProduct

The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

2018

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Italian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their paren…

GerontologyMaleParentsPatient Reported Outcome MeasurePsychometricsHealth StatusArthritisJuvenilePredictive Value of TestHealth StatuDisability Evaluation0302 clinical medicineMedicineImmunology and AllergyFunctional abilityAge of OnsetChildJAMARPatientPrognosisDisease status; Functional ability; Health Related Quality of Life; JAMAR; Juvenile idiopathic arthritis; Adolescent; Age of Onset; Arthritis Juvenile; Case-Control Studies; Child; Child Preschool; Cultural Characteristics; Female; Health Status; Humans; Italy; Male; Parents; Patients; Predictive Value of Tests; Prognosis; Psychometrics; Quality of Life; Reproducibility of Results; Rheumatology; Translating; Disability Evaluation; Patient Reported Outcome MeasuresCultural CharacteristicSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyChild PreschoolPredictive value of testsFemaleCase-Control StudiePsychometricHumanmedicine.medical_specialtyDisease statusAdolescentPatientsPsychometricsPrognosiImmunologyReproducibility of ResultDisease status; Functional ability; Health Related Quality of Life; JAMAR; Juvenile idiopathic arthritis; Rheumatology; Immunology and Allergy; Immunology03 medical and health sciencesJuvenile idiopathic arthritiQuality of life (healthcare)RheumatologyDisease status Functional ability Health Related Quality of Life JAMAR Juvenile idiopathic arthritis Adolescent Age of Onset Arthritis Juvenile Case-Control Studies Child Child Preschool Cultural Characteristics Female Health Status Humans Italy Male Parents Patients Predictive Value of Tests Prognosis Psychometrics Quality of Life Reproducibility of Results Rheumatology Translating Disability Evaluation Patient Reported Outcome MeasuresPredictive Value of Tests030225 pediatricsInternal medicineJuvenileHumansValidation StudiesPatient Reported Outcome MeasuresDisease statuPreschool030203 arthritis & rheumatologyCultural Characteristicsbusiness.industryArthritisReproducibility of ResultsHealth Related Quality of LifeTranslatingJuvenile idiopathic arthritismedicine.diseaseFunctional abilityArthritis JuvenileRheumatologyParentCase-Control StudiesQuality of LifeAge of onsetbusiness
researchProduct

Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational qual…

2006

OBJECTIVES: To compare health-related quality of life (HRQL) and to identify clinical determinants for poor HRQL of patients with juvenile idiopathic arthritis (JIA) coming from three geographic areas.METHODS: The HRQL was assessed through the Child Health Questionnaire (CHQ). A total of 30 countries were included grouped in three geographic areas: 16 countries in Western Europe; 10 in Eastern Europe; and four in Latin America. Potential determinants of poor HRQL included demographic data, physician's and parent's global assessments, measures of joint inflammation, disability as measured by Childhood Health Assessment Questionnaire (CHAQ) and erythrocyte sedimentation rate. Poor HRQL was de…

GerontologyQuality of lifeCross-Cultural ComparisonMalemedicine.medical_specialtyDisability; Juvenile idiopathic arthritis; Pain; Quality of life; Adolescent; Arthritis Juvenile; Child; Cross-Cultural Comparison; Cross-Sectional Studies; Disability Evaluation; Europe; Europe Eastern; Female; Humans; Latin America; Male; Pain Measurement; Severity of Illness Index; Quality of LifeAdolescentCross-sectional studyPainJuvenileEasternSeverity of Illness IndexDisability EvaluationQuality of life (healthcare)RheumatologySeverity of illnessmedicineGlobal healthHumansPharmacology (medical)Europe EasternChildPain MeasurementDisabilitybusiness.industryArthritisJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenilehumanitiesEuropeCross-Sectional StudiesLatin AmericaHealth assessmentPhysical therapyFemalebusinessPsychosocialJuvenile rheumatoid arthritisCohort study
researchProduct